Search

Your search keyword '"Parellada, E."' showing total 240 results
Start Over Author "Parellada, E."
240 results on '"Parellada, E."'

2. Early treatment with JNJ-46356479, a mGluR2 modulator, improves behavioral and neuropathological deficits in a postnatal ketamine mouse model of schizophrenia

Author

Martínez-Pinteño, A., primary, Rodríguez, N., additional, Olivares, D., additional, Madero, S., additional, Gómez, M., additional, Prohens, L., additional, García-Rizo, C., additional, Mas, S., additional, Morén, C., additional, Parellada, E., additional, and Gassó, P., additional

Published
2023
Full Text
View/download PDF

3. Treatment with the positive allosteric modulator of the mglu2 receptor jnj-46356479 modify apoptotic proteins levels in a postnatal murine ketamine-model

Author

Berjaga, D. Olivares, primary, Pinteño, A. Martínez, additional, Rodríguez, N., additional, Madero, S., additional, Arbelo, N., additional, Segura, A. González, additional, Prohens, L., additional, Serrano, I. Martínez, additional, Rizo, C. García, additional, Mas, S., additional, Morén, C., additional, Parellada, E., additional, and Gassó, P., additional

Published
2023
Full Text
View/download PDF

4. Effect of glutamate modulator jnj-46356479 and clozapine on glutamate and gaba brain-levels in a postnatal ketamine mouse model of schizophrenia

Author

Martínez-Pinteño, A., primary, Rodríguez, N., additional, Olivares-Berjaga, D., additional, Madero, S., additional, Prohens, L., additional, Morén, C., additional, García-RIzo, C., additional, Arbelo, N., additional, González-Segura, À., additional, Martínez-Serrano, I., additional, Mas, S., additional, Parellada, E., additional, and Gassó, P., additional

Published
2023
Full Text
View/download PDF

5. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review

Author

González-Rodríguez A, Catalán R, Penadés R, Garcia-Rizo C, Bioque M, Parellada E, and Bernardo M

Subjects
Medicine (General), R5-920
Abstract

Alexandre González-Rodríguez,1 Rosa Catalán,1–4 Rafael Penadés,1–4 Clemente Garcia-Rizo,1,3,4 Miquel Bioque,1,4 Eduard Parellada,1,3–5 Miquel Bernardo1–4 1Barcelona Clinic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clinic of Barcelona, 2Department of Psychiatry and Clinical Psychobiology, University of Barcelona, 3Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; 4Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain; 5Department of Pharmacology, University of Barcelona, Barcelona, Spain Background and objectives: Short-term studies focused on once-monthly paliperidone palmitate (PP) at doses of 25 mg eq, 50 mg eq, 75 mg eq, 100 mg eq, or 150 mg eq have shown its efficacy and tolerability in the treatment of schizophrenia patients. However, few open-label and long-term studies are available regarding this new pharmacological formulation. Thus, our main aim was to review the scientific evidence on efficacy, safety, tolerability, and preference of PP in these populations. Method: Electronic searches were conducted by using PubMed and ISI Web of Knowledge databases. All relevant studies published from 2009 until January 2015 were included without any language restriction if patients met diagnostic criteria for schizophrenia, and adequate information on efficacy, safety, and tolerability of once-monthly PP was available. Results: Nineteen studies were identified irrespective of the study design and duration of the follow-up period. Randomized, double-blind, placebo-controlled trials found that schizophrenia patients receiving PP showed a significant improvement in psychotic symptoms and similar adverse events compared to placebo and suggested that all doses of PP were efficacious and well tolerated. Other studies demonstrated noninferiority of PP compared to risperidone long-acting injectable in recently diagnosed schizophrenia patients, chronically ill patients, as well as in acute and nonacute symptomatic schizophrenia patients, and a similar proportion of treatment-emergent adverse events between both groups were also noted. Conclusion: Several studies have demonstrated that schizophrenia patients treated with PP show higher rates of improvement of psychotic symptoms compared to placebo, and similar efficacy and tolerability outcomes were noted when comparing PP to risperidone long-acting injectable or oral, paliperidone extended release. Keywords: once-monthly paliperidone palmitate, long-acting antipsychotics, psychosis, schizophrenia, safety, efficacy, relapses

Published
2015

13. Birth weight, leptin and adiponectin in patients initiating clozapine.

Author

Ilzarbe, L., Garriga, M., Oliveira, C., Gómez-Ramiro, M., Mallorquí, A., Ruiz-Cortés, V., Rivas, Y., Amoretti, S., Mezquida, G., Ilzarbe, D., Vieta, E., Parellada, E., Baeza, I., and García-Rizo, C.

Subjects
DRUG therapy, BIRTH weight, NEUROHORMONES, PRENATAL influences, LEPTIN
Abstract

Introduction: Psychotic patients often require pharmacological treatment, which may prove ineffective, leading to treatment-resistant psychosis necessitating the use of clozapine. However, the emergence of side effects can result in discontinuation, potentially triggering a relapse of psychotic symptoms. One significant side effect is antipsychotic-induced weight gain which, over time, can lead to adverse metabolic events. Recent translational research is evaluating the impact of prenatal factors on the metabolic outcomes of psychotic patients, using a surrogate marker of the intrauterine milieu such as birth weight (BW). Objectives: We aim to evaluate the changes in leptin, adiponectin, and insulin levels in patients with treatment-resistant psychosis who initiate clozapine treatment due to persistent psychotic symptoms. Methods: Subjects older than 18 years with a diagnostic of a major mental disorder and initiating clozapine were enrolled in this 18-months longitudinal study. Neurohormones levels, including leptin, adiponeptin, and insulin were measured at baseline, 8 and 18 months during follow-up. Statistical analysis were conducted by using a fixed-effects model. Results: A total of 23 subjects initiating clozapine were evaluated during the initial mandatory 18-week period. Neurohormones, specifically leptin and adiponectin, were measured at three time points: baseline, 8 weeks, and 18 weeks. The changes in leptin levels were significantly associated with birth BW with sex differences, being inversely correlated only in females. Adiponectin was significantly associated with BW, being inversely correlated in males. Conversely, there was no observed association between insulin levels and BW. Conclusions: Our findings highlight the significance of prenatal factors in influencing the subsequent evolution of neurohormones in individuals initiating clozapine treatment. This suggests that subjects with lower BW tend to exhibit elevated neurohormone values, emphasizing the role of prenatal events in this context. Disclosure of Interest: None Declared [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort

Author

Mas, S, Gasso, P, Rodriguez, N, Cabrera, B, Mezquida, G, Lobo, A, Gonzalez-Pinto, A, Parellada, M, Corripio, I, Vieta, E, Castro-Fornieles, J, Bobes, J, Usall, J, Saiz-Ruiz, J, Contreras, F, Parellada, E, Bernardo, M, Lafuente, A, Bioque, M, Diaz-Caneja, CM, Gonzalez-Penas, J, Solis, AA, Rebella, M, Gonzalez-Ortega, I, Besga, A, SanJuan, J, Nacher, J, Morro, L, Montserrat, C, Jimenez, E, Da Costa, SG, Baeza, I, de la Serna, E, Rivas, S, Diaz, C, Saiz, PA, Garcia-Alvarez, L, Fraile, MG, Rabadan, AZ, Torio, I, Rodriguez-Jimenez, R, Butjosa, A, Pardo, M, Sarro, S, Pomarol-Clotet, E, Cuadrado, AI, and Cuesta, MJ

Subjects
predictive factors, psychosis, personalized medicine, first-episode, antipsychotic, clustering
Abstract

Aims Here, we present a clustering strategy to identify phenotypes of antipsychotic (AP) response by using longitudinal data from patients presenting first-episode psychosis (FEP). Method One hundred and ninety FEP with complete data were selected from the PEPs project. The efficacy was assessed using total PANSS, and adverse effects using total UKU, during one-year follow-up. We used the Klm3D method to cluster longitudinal data. Results We identified four clusters: cluster A, drug not toxic and beneficial; cluster B, drug beneficial but toxic; cluster C, drug neither toxic nor beneficial; and cluster D, drug toxic and not beneficial. These groups significantly differ in baseline demographics, clinical, and neuropsychological characteristics (PAS, total PANSS, DUP, insight, pIQ, age of onset, cocaine use and family history of mental illness). Conclusions The results presented here allow the identification of phenotypes of AP response that differ in well-known simple and classic clinical variables opening the door to clinical prediction and application of personalized medicine.

Published
2020

15. Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort

Author

Mas S, Gasso P, Rodriguez N, Cabrera B, Mezquida G, Lobo A, Gonzalez-Pinto A, Parellada M, Corripio I, Vieta E, Castro-Fornieles J, Bobes J, Usall J, Saiz-Ruiz J, Contreras F, Parellada E, Bernardo M, Lafuente A, Bioque M, Diaz-Caneja C, Gonzalez-Penas J, Solis A, Rebella M, Gonzalez-Ortega I, Besga A, Sanjuan J, Nacher J, Morro L, Montserrat C, Jimenez E, Da Costa S, Baeza I, de la Serna E, Rivas S, Diaz C, Saiz P, Garcia-Alvarez L, Fraile M, Rabadan A, Torio I, Rodriguez-Jimenez R, Butjosa A, Pardo M, Sarro S, Pomarol-Clotet E, Cuadrado A, Cuesta M, and PEPs Grp

Subjects
predictive factors, psychosis, personalized medicine, first-episode, antipsychotic, clustering
Abstract

Aims Here, we present a clustering strategy to identify phenotypes of antipsychotic (AP) response by using longitudinal data from patients presenting first-episode psychosis (FEP). Method One hundred and ninety FEP with complete data were selected from the PEPs project. The efficacy was assessed using total PANSS, and adverse effects using total UKU, during one-year follow-up. We used the Klm3D method to cluster longitudinal data. Results We identified four clusters: cluster A, drug not toxic and beneficial; cluster B, drug beneficial but toxic; cluster C, drug neither toxic nor beneficial; and cluster D, drug toxic and not beneficial. These groups significantly differ in baseline demographics, clinical, and neuropsychological characteristics (PAS, total PANSS, DUP, insight, pIQ, age of onset, cocaine use and family history of mental illness). Conclusions The results presented here allow the identification of phenotypes of AP response that differ in well-known simple and classic clinical variables opening the door to clinical prediction and application of personalized medicine.

Published
2020

21. Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients

Author

Catafau, A.M., Penengo, M.M., Nucci, G., Bullich, S., Corripio, I., Parellada, E., Garcia-Ribera, C., Gomeni, R., and Merlo-Pich, E.

Subjects
Dopamine receptors -- Health aspects, Schizophrenics -- Care and treatment, Pharmacokinetics -- Research, Antipsychotic drugs -- Usage, Antipsychotic drugs -- Health aspects, Pharmaceuticals and cosmetics industries, Psychology and mental health
Published
2008

22. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

Author

Parellada, E., Andrezina, R., Milanova, V., Glue, P., Masiak, M., Turner, M. St. John, Medori, R., and Gaebel, W.

Subjects
Schizoaffective disorders -- Diagnosis -- Care and treatment, Schizophrenia -- Diagnosis -- Care and treatment, Pharmaceuticals and cosmetics industries, Psychology and mental health, Diagnosis, Care and treatment
Abstract

Abstract The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (≤ 3 years). Patients who required a [...]

Published
2005

27. Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls

Author

Batalla, A., Bargallo, N., Gasso, P., Molina, O., Pareto, D., Mas, S., Roca, J.M., Bernardo, M., Lafuente, A., Parellada, E., Batalla, A., Bargallo, N., Gasso, P., Molina, O., Pareto, D., Mas, S., Roca, J.M., Bernardo, M., Lafuente, A., and Parellada, E.

Abstract

Contains fulltext : 152783.pdf (publisher's version ) (Open Access), Cultured fibroblasts from first-episode schizophrenia patients (FES) have shown increased susceptibility to apoptosis, which may be related to glutamate dysfunction and progressive neuroanatomical changes. Here we determine whether apoptotic markers obtained from cultured fibroblasts in FES and controls correlate with changes in brain glutamate and N-acetylaspartate (NAA) and regional brain volumes. Eleven antipsychotic-naive FES and seven age- and gender-matched controls underwent 3-Tesla magnetic resonance imaging scanning. Glutamate plus glutamine (Glx) and NAA levels were measured in the anterior cingulate (AC) and the left thalamus (LT). Hallmarks of apoptotic susceptibility (caspase-3-baseline activity, phosphatidylserine externalization and chromatin condensation) were measured in fibroblast cultures obtained from skin biopsies after inducing apoptosis with staurosporine (STS) at doses of 0.25 and 0.5 muM. Apoptotic biomarkers were correlated to brain metabolites and regional brain volume. FES and controls showed a negative correlation in the AC between Glx levels and percentages of cells with condensed chromatin (CC) after both apoptosis inductions (STS 0.5 muM: r = -0.90; P = 0.001; STS 0.25 muM: r = -0.73; P = 0.003), and between NAA and cells with CC (STS 0.5 muM induction r = -0.76; P = 0.002; STS 0.25 muM r = -0.62; P = 0.01). In addition, we found a negative correlation between percentages of cells with CC and regional brain volume in the right supratemporal cortex and post-central region (STS 0.25 and 0.5 muM; P < 0.05 family-wise error corrected (FWEc)). We reveal for the first time that peripheral markers of apoptotic susceptibility may correlate with brain metabolites, Glx and NAA, and regional brain volume in FES and controls, which is consistent with the neuroprogressive theories around the onset of the schizophrenia illness.

Published
2015

33. EPA-1551 - Paliperidone palmitate – impact on negative, disorganized and depressive symptoms, subjective well-being and patient satisfaction in patients with schizophrenia previously unsuccessfully treated with oral antipsychotics

Author

Schreiner, A., primary, Hargarter, L., additional, Bergmans, P., additional, Cherubin, P., additional, Rancans, E., additional, Bez, Y., additional, Parellada, E., additional, Carpiniello, B., additional, and Vidailhet, P., additional

Published
2014
Full Text
View/download PDF

34. EPA-1545 - Functional outcomes with once-monthly paliperidone palmitate in acute and in non-acute patients with schizophrenia previously unsuccessfully treated with oral antipsychotics

Author

Hargarter, L., primary, Bergmans, P., additional, Cherubin, P., additional, Björner, A., additional, Knegtering, R., additional, Parellada, E., additional, Carpiniello, B., additional, Vidailhet, P., additional, Mertens, C., additional, and Schreiner, A., additional

Published
2014
Full Text
View/download PDF

35. EPA-1547 - Once monthly paliperidone palmitate – tolerability and treatment response in recently diagnosed versus chronic non-acute schizophrenia patients switched from previously unsuccessful treatment with oral antipsychotics

Author

Hargarter, L., primary, Bergmans, P., additional, Cherubin, P., additional, Rancans, E., additional, Bez, Y., additional, Parellada, E., additional, Carpiniello, B., additional, Vidailhet, P., additional, and Schreiner, A., additional

Published
2014
Full Text
View/download PDF

39. EPA-1550 - Paliperidone palmitate in acute patients with schizophrenia: treatment response, safety and tolerability ? a prospective flexible-dose study in patients previously unsuccessfully treated with oral antipsychotics

Author

Schreiner, A., primary, Bergmans, P., additional, Cherubin, P., additional, Rancans, E., additional, Bez, Y., additional, Parellada, E., additional, Carpiniello, B., additional, Vidailhet, P., additional, and Hargarter, L., additional

Published
2014
Full Text
View/download PDF

42. Réponse thérapeutique, tolérance et sécurité d’emploi du palmitate de palipéridone à dose flexible : une étude prospective chez des patients adultes non-aigus atteints de schizophrénie, après échec d’un traitement par antipsychotiques oraux

Author

Vidailhet, P., primary, Schreiner, A., additional, Bergmans, P., additional, Cherubin, P., additional, Rancans, E., additional, Bez, Y., additional, Parellada, E., additional, Carpiniello, B., additional, and Hargater, L., additional

Published
2013
Full Text
View/download PDF

43. Amélioration fonctionnelle sous palmitate de paliperidone à doses flexibles chez des patients aigus ou non aigus atteints de schizophrénie, après échec d’un traitement par antipsychotiques oraux

Author

Hargarter, L., primary, Bergmans, B., additional, Cherubin, P., additional, Bjorner, A., additional, Knegtering, H., additional, Parellada, E., additional, Carpiniello, B., additional, Vidailhet, P., additional, Mertens, C., additional, and Schreiner, A., additional

Published
2013
Full Text
View/download PDF

44. Palmitate de palipéridone à doses flexibles chez des patients non-aigus atteints de schizophrénie après échec d’un autre traitement par antipsychotiques injectables à action prolongée

Author

Cherubin, P., primary, Hargater, L., additional, Bergmans, B., additional, Bjorner, A., additional, Knegtering, H., additional, Parellada, E., additional, Carpiniello, B., additional, Vidailhet, P., additional, Mertens, C., additional, and Schreiner, A., additional

Published
2013
Full Text
View/download PDF

45. Palmitate de palipéridone à doses flexibles – Réponse thérapeutique, tolérance et sécurité d’emploi: une étude prospective chez des patients en période d’exacerbation aiguë d’un trouble schizophrénique après échec d’un traitement par antipsychotiques oraux

Author

Schreiner, A., primary, Bergmans, P., additional, Cherubin, P., additional, Rancans, E., additional, Bez, Y., additional, Parellada, E., additional, Carpiniello, B., additional, Vidailhet, P., additional, and Hargater, L., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results